ART100 Becomes Inspira’s First System to Complete Clinical Evaluation and Enters Budgeted Procurement at Top U.S. Medical Center

Core Insights - Inspira Technologies has successfully completed the clinical evaluation of its FDA-cleared INSPIRA™ ART100 system, which is now moving to a budgeted procurement process at a leading U.S. academic medical center [1][3] Group 1: Clinical Evaluation and Procurement - The ART100 system is the first of its kind at this institution to transition from pilot use to standard clinical workflow after treating approximately 30 patients across various medical indications, including life-saving procedures, surgeries, and transplants [2][3] - Following the completion of the clinical phase, the medical center has initiated an internal procurement process for multiple ART100 systems, which is now subject to budget release [3] Group 2: Company Positioning and Technology Validation - The CEO of Inspira Technologies highlighted that reaching this milestone at a top academic medical center validates the clinical value and reliability of the ART100 technology, which has been integrated into routine workflow due to positive feedback from medical staff [4] - The completion of the clinical phase and the advancement to procurement is seen as a significant strengthening of the company's U.S. commercial positioning and supports broader adoption of the ART100 platform across leading healthcare institutions [4] Group 3: Company Overview - Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions, with the ART100 system approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. [5] - The company is also developing the INSPIRA ART500, a next-generation system designed for oxygenation while patients remain awake, and advancing the HYLA™ blood sensor platform for continuous, non-invasive monitoring [5]